메뉴 건너뛰기




Volumn 18, Issue 7, 2011, Pages 1118-1124

KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis

Author keywords

[No Author keywords available]

Indexed keywords

A2 PROTEIN; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE B; KINETOPLASTID MEMBRANE PROTEIN 11; LEISHMANIA VACCINE; METHYLTRANSFERASE; POLYPROTEIN; PROTOZOAL PROTEIN; STEROL 24 C METHYLTRANSFERASE; UNCLASSIFIED DRUG;

EID: 79960130905     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05024-11     Document Type: Article
Times cited : (70)

References (47)
  • 1
    • 17344374265 scopus 로고    scopus 로고
    • Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: Safety, immunogenicity, and efficacy during the first 12 months of follow-up
    • Armijos, R. X., M. M. Weigel, H. Aviles, R. Maldonado, and J. Racines. 1998. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J. Infect. Dis. 177:1352-1357.
    • (1998) J. Infect. Dis. , vol.177 , pp. 1352-1357
    • Armijos, R.X.1    Weigel, M.M.2    Aviles, H.3    Maldonado, R.4    Racines, J.5
  • 2
    • 33749648396 scopus 로고    scopus 로고
    • Immunotherapy for drug-refractory mucosal leishmaniasis
    • Badaro, R., et al. 2006. Immunotherapy for drug-refractory mucosal leishmaniasis. J. Infect. Dis. 194:1151-1159.
    • (2006) J. Infect. Dis. , vol.194 , pp. 1151-1159
    • Badaro, R.1
  • 3
    • 18944378937 scopus 로고    scopus 로고
    • Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: Evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis
    • Basu, R., et al. 2005. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol. 174:7160-7171.
    • (2005) J. Immunol. , vol.174 , pp. 7160-7171
    • Basu, R.1
  • 5
    • 70350569335 scopus 로고    scopus 로고
    • Optimized subunit vaccine protects against experimental leishmaniasis
    • Bertholet, S., et al. 2009. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27:7036-7045.
    • (2009) Vaccine , vol.27 , pp. 7036-7045
    • Bertholet, S.1
  • 6
    • 59849102406 scopus 로고    scopus 로고
    • KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major
    • Bhaumik, S., R. Basu, S. Sen, K. Naskar, and S. Roy. 2009. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine 27:1306-1316.
    • (2009) Vaccine , vol.27 , pp. 1306-1316
    • Bhaumik, S.1    Basu, R.2    Sen, S.3    Naskar, K.4    Roy, S.5
  • 7
    • 0035001263 scopus 로고    scopus 로고
    • Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease
    • Campos-Neto, A., et al. 2001. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect. Immun. 69:4103-4108.
    • (2001) Infect. Immun. , vol.69 , pp. 4103-4108
    • Campos-Neto, A.1
  • 8
    • 0022369062 scopus 로고
    • Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis
    • Carvalho, E. M., R. Badaro, S. G. Reed, T. C. Jones, and W. D. Johnson, Jr. 1985. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin. Invest. 76:2066-2069.
    • (1985) J. Clin. Invest. , vol.76 , pp. 2066-2069
    • Carvalho, E.M.1    Badaro, R.2    Reed, S.G.3    Jones, T.C.4    Johnson Jr., W.D.5
  • 9
    • 34547870667 scopus 로고    scopus 로고
    • Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD(4+) T cells
    • Coler, R. N., Y. Goto, L. Bogatzki, V. Raman, and S. G. Reed. 2007. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD(4+) T cells. Infect. Immun. 75:4648-4654.
    • (2007) Infect. Immun. , vol.75 , pp. 4648-4654
    • Coler, R.N.1    Goto, Y.2    Bogatzki, L.3    Raman, V.4    Reed, S.G.5
  • 10
    • 17444429293 scopus 로고    scopus 로고
    • Second-generation vaccines against leishmaniasis
    • Coler, R. N., and S. G. Reed. 2005. Second-generation vaccines against leishmaniasis. Trends Parasitol. 21:244-249.
    • (2005) Trends Parasitol. , vol.21 , pp. 244-249
    • Coler, R.N.1    Reed, S.G.2
  • 11
    • 0036073291 scopus 로고    scopus 로고
    • Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis
    • DOI 10.1128/IAI.70.8.4215-4225.2002
    • Coler, R. N., et al. 2002. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stressinducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70:4215-4225. (Pubitemid 34790930)
    • (2002) Infection and Immunity , vol.70 , Issue.8 , pp. 4215-4225
    • Coler, R.N.1    Skeiky, Y.A.W.2    Bernards, K.3    Greeson, K.4    Carter, D.5    Cornellison, C.D.6    Modabber, F.7    Campos-Neto, A.8    Reed, S.G.9
  • 13
    • 53449090936 scopus 로고    scopus 로고
    • Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein
    • Fernandes, A. P., et al. 2008. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 26:5888-5895.
    • (2008) Vaccine , vol.26 , pp. 5888-5895
    • Fernandes, A.P.1
  • 14
    • 0035850989 scopus 로고    scopus 로고
    • Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections
    • DOI 10.1016/S0264-410X(01)00322-X, PII S0264410X0100322X
    • Ghosh, A., W. W. Zhang, and G. Matlashewski. 2001. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20:59-66. (Pubitemid 32905314)
    • (2001) Vaccine , vol.20 , Issue.1-2 , pp. 59-66
    • Ghosh, A.1    Zhang, W.W.2    Matlashewski, G.3
  • 15
    • 64449087496 scopus 로고    scopus 로고
    • Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection
    • Goto, Y., et al. 2009. Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection. Vaccine 27:2884-2890.
    • (2009) Vaccine , vol.27 , pp. 2884-2890
    • Goto, Y.1
  • 16
    • 34748876077 scopus 로고    scopus 로고
    • Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant
    • Goto, Y., L. Y. Bogatzki, S. Bertholet, R. N. Coler, and S. G. Reed. 2007. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 25:7450-7458.
    • (2007) Vaccine , vol.25 , pp. 7450-7458
    • Goto, Y.1    Bogatzki, L.Y.2    Bertholet, S.3    Coler, R.N.4    Reed, S.G.5
  • 17
    • 60849092883 scopus 로고    scopus 로고
    • Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs
    • Goto, Y., et al. 2009. Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs. Vet. Parasitol. 160:215-220.
    • (2009) Vet. Parasitol. , vol.160 , pp. 215-220
    • Goto, Y.1
  • 18
    • 26644448719 scopus 로고    scopus 로고
    • Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals
    • Gradoni, L., et al. 2005. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 23:5245-5251.
    • (2005) Vaccine , vol.23 , pp. 5245-5251
    • Gradoni, L.1
  • 19
    • 0021075679 scopus 로고
    • Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis
    • Haldar, J. P., S. Ghose, K. C. Saha, and A. C. Ghose. 1983. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect. Immun. 42:702-707.
    • (1983) Infect. Immun. , vol.42 , pp. 702-707
    • Haldar, J.P.1    Ghose, S.2    Saha, K.C.3    Ghose, A.C.4
  • 20
    • 0034193027 scopus 로고    scopus 로고
    • In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease
    • Himmelrich, H., et al. 2000. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J. Immunol. 164:4819-4825.
    • (2000) J. Immunol. , vol.164 , pp. 4819-4825
    • Himmelrich, H.1
  • 21
    • 0034605714 scopus 로고    scopus 로고
    • Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: A randomised, double-blind, BCG-controlled trial in Sudan
    • Khalil, E. A., et al. 2000. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356:1565-1569.
    • (2000) Lancet , vol.356 , pp. 1565-1569
    • Khalil, E.A.1
  • 22
    • 77952725081 scopus 로고    scopus 로고
    • Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine
    • Kumar, R., et al. 2010. Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine. Am. J. Trop. Med. Hyg. 82:808-813.
    • (2010) Am. J. Trop. Med. Hyg. , vol.82 , pp. 808-813
    • Kumar, R.1
  • 23
    • 0030588671 scopus 로고    scopus 로고
    • The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice: A tissue-dependent pattern controlled by the Lsh and MHC loci
    • Leclercq, V., M. Lebastard, Y. Belkaid, J. Louis, and G. Milon. 1996. The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice: a tissue-dependent pattern controlled by the Lsh and MHC loci. J. Immunol. 157:4537-4545.
    • (1996) J. Immunol. , vol.157 , pp. 4537-4545
    • Leclercq, V.1    Lebastard, M.2    Belkaid, Y.3    Louis, J.4    Milon, G.5
  • 24
    • 0025609915 scopus 로고
    • Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide
    • Liew, F. Y., Y. Li, and S. Millott. 1990. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J. Immunol. 145:4306-4310.
    • (1990) J. Immunol. , vol.145 , pp. 4306-4310
    • Liew, F.Y.1    Li, Y.2    Millott, S.3
  • 25
    • 77958184848 scopus 로고    scopus 로고
    • A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis
    • Llanos-Cuentas, A., et al. 2010. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 28:7427-7435.
    • (2010) Vaccine , vol.28 , pp. 7427-7435
    • Llanos-Cuentas, A.1
  • 26
    • 40049107841 scopus 로고    scopus 로고
    • Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis
    • Miret, J., et al. 2008. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine 26:1585-1594.
    • (2008) Vaccine , vol.26 , pp. 1585-1594
    • Miret, J.1
  • 27
    • 34250853431 scopus 로고    scopus 로고
    • Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis
    • Moreno, J., et al. 2007. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 25:5290-5300.
    • (2007) Vaccine , vol.25 , pp. 5290-5300
    • Moreno, J.1
  • 28
    • 0029030456 scopus 로고
    • Expression cloning of a protective Leishmania antigen
    • Mougneau, E., et al. 1995. Expression cloning of a protective Leishmania antigen. Science 268:563-566.
    • (1995) Science , vol.268 , pp. 563-566
    • Mougneau, E.1
  • 29
    • 0033785362 scopus 로고    scopus 로고
    • Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment
    • Murray, H. W., A. Jungbluth, E. Ritter, C. Montelibano, and M. W. Marino. 2000. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect. Immun. 68:6289-6293.
    • (2000) Infect. Immun. , vol.68 , pp. 6289-6293
    • Murray, H.W.1    Jungbluth, A.2    Ritter, E.3    Montelibano, C.4    Marino, M.W.5
  • 30
    • 0027164877 scopus 로고
    • Role and effect of IL-2 in experimental visceral leishmaniasis
    • Murray, H. W., G. D. Miralles, M. Y. Stoeckle, and D. F. McDermott. 1993. Role and effect of IL-2 in experimental visceral leishmaniasis. J. Immunol. 151:929-938.
    • (1993) J. Immunol. , vol.151 , pp. 929-938
    • Murray, H.W.1    Miralles, G.D.2    Stoeckle, M.Y.3    McDermott, D.F.4
  • 31
    • 77956432699 scopus 로고    scopus 로고
    • A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis
    • Nascimento, E., et al. 2010. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 28:6581-6587.
    • (2010) Vaccine , vol.28 , pp. 6581-6587
    • Nascimento, E.1
  • 32
    • 56949106494 scopus 로고    scopus 로고
    • First generation leishmaniasis vaccines: A review of field efficacy trials
    • Noazin, S., et al. 2008. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 26:6759-6767.
    • (2008) Vaccine , vol.26 , pp. 6759-6767
    • Noazin, S.1
  • 33
    • 40649091062 scopus 로고    scopus 로고
    • Vaccines for leishmaniasis in the fore coming 25 years
    • Palatnik-de-Sousa, C. B. 2008. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 26:1709-1724.
    • (2008) Vaccine , vol.26 , pp. 1709-1724
    • Palatnik-De-Sousa, C.B.1
  • 34
    • 21044441505 scopus 로고    scopus 로고
    • Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum
    • DOI 10.1016/j.vaccine.2005.02.009, PII S0264410X05002690
    • Rafati, S., et al. 2005. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23:3716-3725. (Pubitemid 40692418)
    • (2005) Vaccine , vol.23 , Issue.28 , pp. 3716-3725
    • Rafati, S.1    Nakhaee, A.2    Taheri, T.3    Taslimi, Y.4    Darabi, H.5    Eravani, D.6    Sanos, S.7    Kaye, P.8    Taghikhani, M.9    Jamshidi, S.10    Rad, M.A.11
  • 35
    • 0035858106 scopus 로고    scopus 로고
    • A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major
    • DOI 10.1016/S0264-410X(01)00081-0, PII S0264410X01000810
    • Rafati, S., A. H. Salmanian, T. Taheri, M. Vafa, and N. Fasel. 2001. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 19:3369-3375. (Pubitemid 32710285)
    • (2001) Vaccine , vol.19 , Issue.25-26 , pp. 3369-3375
    • Rafati, S.1    Salmanian, A.-H.2    Taheri, T.3    Vafa, M.4    Fasel, N.5
  • 36
    • 32844459122 scopus 로고    scopus 로고
    • Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis
    • Rafati, S., F. Zahedifard, and F. Nazgouee. 2006. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24:2169-2175.
    • (2006) Vaccine , vol.24 , pp. 2169-2175
    • Rafati, S.1    Zahedifard, F.2    Nazgouee, F.3
  • 37
    • 0023886330 scopus 로고
    • Effective immunization cutaneous leishmaniasis with defined membrane antigens reconsituted into liposomes
    • Russell, D. G., and J. Alexander. 1988. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J. Immunol. 140:1274-1279. (Pubitemid 18096704)
    • (1988) Journal of Immunology , vol.140 , Issue.4 , pp. 1274-1279
    • Russell, D.G.1    Alexander, J.2
  • 38
    • 0001902784 scopus 로고    scopus 로고
    • Animal models for the analysis of immune responses to leishmaniasis
    • Chapter 19, Unit 19.2
    • Sacks, D. L., and P. C. Melby. 2001. Animal models for the analysis of immune responses to leishmaniasis. Curr. Protoc. Immunol. 2001:Chapter 19, Unit 19.2.
    • (2001) Curr. Protoc. Immunol. , vol.2001
    • Sacks, D.L.1    Melby, P.C.2
  • 39
    • 0025133974 scopus 로고
    • Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism
    • Sadick, M. D., et al. 1990. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J. Exp. Med. 171:115-127.
    • (1990) J. Exp. Med. , vol.171 , pp. 115-127
    • Sadick, M.D.1
  • 40
    • 7144254432 scopus 로고    scopus 로고
    • Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran
    • Sharifi, I., et al. 1998. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351:1540-1543.
    • (1998) Lancet , vol.351 , pp. 1540-1543
    • Sharifi, I.1
  • 41
    • 0028929566 scopus 로고
    • A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12
    • Skeiky, Y. A., et al. 1995. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J. Exp. Med. 181:1527-1537.
    • (1995) J. Exp. Med. , vol.181 , pp. 1527-1537
    • Skeiky, Y.A.1
  • 42
    • 0032403592 scopus 로고    scopus 로고
    • LeIF: A recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile
    • Skeiky, Y. A., et al. 1998. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol. 161:6171-6179.
    • (1998) J. Immunol. , vol.161 , pp. 6171-6179
    • Skeiky, Y.A.1
  • 44
    • 0034671822 scopus 로고    scopus 로고
    • Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis
    • Stager, S., D. F. Smith, and P. M. Kaye. 2000. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 165:7064-7071.
    • (2000) J. Immunol. , vol.165 , pp. 7064-7071
    • Stager, S.1    Smith, D.F.2    Kaye, P.M.3
  • 45
    • 77950627826 scopus 로고    scopus 로고
    • Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE
    • Trigo, J., et al. 2010. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine 28:3333-3340.
    • (2010) Vaccine , vol.28 , pp. 3333-3340
    • Trigo, J.1
  • 46
    • 0031842834 scopus 로고    scopus 로고
    • Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family
    • Webb, J. R., et al. 1998. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 66:3279-3289.
    • (1998) Infect. Immun. , vol.66 , pp. 3279-3289
    • Webb, J.R.1
  • 47
    • 0030457804 scopus 로고    scopus 로고
    • Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis
    • Webb, J. R., D. Kaufmann, A. Campos-Neto, and S. G. Reed. 1996. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 157:5034-5041.
    • (1996) J. Immunol. , vol.157 , pp. 5034-5041
    • Webb, J.R.1    Kaufmann, D.2    Campos-Neto, A.3    Reed, S.G.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.